Application Of Adoptive Immunotherapy In Ovarian Cancer

Siyu Yang1
Xiaojiao Yin1
Ying Yue1
Siqing Wang2

1Department of Gynecological Oncology, The First Hospital of Jilin University, Changchun 130061, China; 2Department of Cancer Immunology, The First Hospital of Jilin University, Changchun 130061, China

Abstract: Ovarian cancer (OC) has been the most fatal gynecological disease that threatens women’s health. Surgery and platinum-based chemotherapy are the basic ovarian cancer treatments that can improve survival, but the five-year survival rate has not improved because of delayed diagnosis, drug resistance, and recurrence. Novel treatments are needed to improve the prognosis and survival rate of ovarian cancer patients. In recent years, adoptive cell therapy (ACT) has received increasing attention as an emerging therapeutic strategy in the treatment of solid tumors including OC. ACT has shown promising results in many preclinical and clinical trials of OC. The application of ACT depends on different effector cells, such as lymphokine-activated killer (LAK) cells, tumor-infiltrating lymphocytes (TILs), and genetically modified T cells. In this review, we focus on adoptive immunotherapies in ovarian cancer and summarize completed and ongoing preclinical/clinical trials. The future development directions and obstacles for ACT in OC treatment are discussed.

Keywords: ovarian cancer, adoptive cell therapy, cancer immunotherapy, immune cells

Introduction

Ovarian cancer (OC) is the primary gynecological causes of death in women. Worldwide, there are about 230,000 cases of OC each year, with more than 150,000 deaths.1 Surgery and chemotherapy are currently the main treatments for OC. Cytoreductive surgery is used to remove all visible tumor masses. However, most patients are diagnosed in the advanced stage of the tumor and need to receive postoperative adjuvant chemotherapy. In addition, patients with extensive tumor metastasis will receive neoadjuvant chemotherapy to shrink the tumor and destroy metastatic cells, so as to facilitate subsequent surgery and other treatments.2–4 Although radical surgery and adjuvant chemotherapy are performed to remove macroscopic tumors and improve outcomes, most patients with ovarian cancer will have recurrence and tumor resistance, which is usually fatal5 and widely studied anti-vascular endothelial growth factor (VEGF) therapy is also difficult to reverse this situation6 [Table 1]. Thus, there is a great need for more effective OC therapies to improve the long-term clinical prognosis.

With the improved understanding of the relationship between the immune system and tumor development, immunotherapy is becoming a promising treatment for lung cancer,15 melanoma,16 liver cancer,17 and breast cancer.18 In recent years, increasing evidence has shown that immunotherapy is also a promising treatment in ovarian cancer since ovarian cancer is an immunogenic tumor that can be recognized and attacked by immune system.19–21 Recent immune therapies mainly include immune checkpoint inhibitors, cancer vaccine, and adoptive cell therapy
Among them, ACT has attracted increasing attention because a large number of specific effector cells against tumor cells results in a quick therapeutic effect and minimizes impact on the internal environment than other therapies.

ACT relies on intravenous infusion of autologous immune cells after stimulation/modification and expansion in vitro to improve autologous antitumor response in tumor patients. In 1965, Mathé et al confirmed that adoptive immunotherapy had an obvious effect on acute leukemia in a murine experiment and clinical trial. Research on ACT for the treatment of hematological malignancies is constantly evolving and developing.

In 2002, a clinical trial showed that adoptive cell immunotherapy was effective for solid tumors (metastatic melanoma) and ongoing clinical trials have confirmed this. Since OC was not originally considered to be an immunogenic tumor, adoptive immunotherapy for OC did not initially receive much attention. However, in 2003, OC was shown to be an immunogenic tumor that may be treat by immunotherapy. Adaptive immunotherapy is based on different cell types: MHC-independent cells (e.g., lymphokine-activated killer (LAK) cells, natural killer (NK) cells, and cytokine-induced killer (CIK) cells) or MHC-dependent cells (tumor-infiltrating lymphocytes (TILs)). There are also two special and rapidly developing cell types: chimeric antigen receptor (CAR) T cells and T cell receptor (TCR) T cells.

In this review, we discuss the application of adoptive immunotherapy of LAK cells, NK cells, CIK cells, TILs, CAR-T cells, and TCR-T cells in OC and outline the disadvantages and future development directions of ACT in OC treatment.

### Major Histocompatibility Complex (MHC)-Independent Adoptive Immunotherapy

#### LAK Cells

LAK cells are induced by NK cells or T cells through adding high-dose IL-2 and other cytokines when cultured in vitro, rather than an independent lymphoid or subgroup. LAK cells can kill NK-instant tumor cells and have achieved certain therapeutic effects in cancer treatment. In 1985, Rosenberg et al suggested that LAK cells and IL-2 adoptive immunotherapy have therapeutic effects on metastatic tumors for which many traditional treatments are ineffective. Although the number of clinical patients in this study was limited, the same authors had

| Therapy      | Clinical Efficacy Comparison                                                                 | Reference |
|--------------|---------------------------------------------------------------------------------------------|-----------|
| Surgery      | 1. Surgical treatment and chemotherapy are usually used in combination in clinical practice, not alone.  
2. Primary surgery combined with postoperative platinum-taxane chemotherapy has been the standard therapy for advanced ovarian cancer.  
The progression-free and overall survival of complete resection (ideally with no macroscopic residual disease) are improved compared with so-called optimal and suboptimal debulking resection. | 7         |
| Chemotherapy | 1. Chemotherapy is a milestone in the treatment of ovarian cancer because it improves the outcome in women with ovarian cancer. It can help to achieve no residual tumor (R0) after primary debulking surgery (PDS), or to treat patients by neoadjuvant chemotherapy (NACT).  
2. The clinical efficacy of chemotherapy depends on various factors such as dose, choice of platinum and/or taxane, schedule, mode of administration (intravenous [IV], intraperitoneal [IP]) and so on.  
3. However, some patients will have chemotherapy resistance, and many patients who are cured by chemotherapy will relapse. | 8         |
| Anti-VEGF treatment | 1. Bevacizumab is the most widely studied anti-angiogenesis agent in ovarian cancer.  
2. Two large phase III trials shown that chemotherapy with the addition of bevacizumab significantly improved the progression free survival (PFS) of patients.  
3. However, there is also evidence that bevacizumab has toxicity and side effects such as gastrointestinal (GI) perforation, surgery and wound-healing complications, and hemorrhage.  
4. Only a subset of patients will benefit from anti-angiogenic agents | 9–11      |
| Immunotherapy | Tumor immunotherapy, such as anti-PD-L1/PD-1 therapies and adoptive therapy, have subsequently demonstrated significant anti-tumor effects. Although immunotherapy is still in its infancy in the clinical treatment of ovarian cancer, many promising preclinical experiments indicate its potential. | 12–14     |

### Table 1 Comparison Of Clinical Effects Of Four Ovarian Cancer Treatment Methods

| Therapy     | Clinical Efficacy Comparison                                                                                                                                                                                                 | Reference |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Surgery     | 1. Surgical treatment and chemotherapy are usually used in combination in clinical practice, not alone.  
2. Primary surgery combined with postoperative platinum-taxane chemotherapy has been the standard therapy for advanced ovarian cancer.  
The progression-free and overall survival of complete resection (ideally with no macroscopic residual disease) are improved compared with so-called optimal and suboptimal debulking resection. | 7         |
| Chemotherapy| 1. Chemotherapy is a milestone in the treatment of ovarian cancer because it improves the outcome in women with ovarian cancer. It can help to achieve no residual tumor (R0) after primary debulking surgery (PDS), or to treat patients by neoadjuvant chemotherapy (NACT).  
2. The clinical efficacy of chemotherapy depends on various factors such as dose, choice of platinum and/or taxane, schedule, mode of administration (intravenous [IV], intraperitoneal [IP]) and so on.  
3. However, some patients will have chemotherapy resistance, and many patients who are cured by chemotherapy will relapse. | 8         |
| Anti-VEGF   | 1. Bevacizumab is the most widely studied anti-angiogenesis agent in ovarian cancer.  
2. Two large phase III trials shown that chemotherapy with the addition of bevacizumab significantly improved the progression free survival (PFS) of patients.  
3. However, there is also evidence that bevacizumab has toxicity and side effects such as gastrointestinal (GI) perforation, surgery and wound-healing complications, and hemorrhage.  
4. Only a subset of patients will benefit from anti-angiogenic agents | 9–11      |
| Immunotherapy| Tumor immunotherapy, such as anti-PD-L1/PD-1 therapies and adoptive therapy, have subsequently demonstrated significant anti-tumor effects. Although immunotherapy is still in its infancy in the clinical treatment of ovarian cancer, many promising preclinical experiments indicate its potential. | 12–14      |
also shown promising therapeutic effects in their previous in vivo experiments in mice; however, they also mentioned that high-dose IL-2 promotes the secretion of toxic cytokines by helper T cells, which is harmful to patients. Grimm et al also described this problem. Although LAK cell adoptive immunotherapy has a very broad-spectrum anti-tumor effect, the safe application of high-dose IL-2 is still problematic.

**NK Cells**

NK cells are part of the innate immune response and are key effectors in cancer immunosurveillance. They can defend against cancer development and metastasis without restricting the expression of MHC molecules. NK cells represent about 5–15% of human circulating lymphocytes and comprise CD56<sup>hi</sup>CD16<sup>−</sup> NK cells and CD56<sup>lo</sup>CD16<sup>+</sup> NK cells. CD56<sup>hi</sup>CD16<sup>−</sup> NK cells with high cytotoxic potential can produce plenty of cytokines, while CD56<sup>lo</sup>CD16<sup>+</sup> NK cells are highly cytotoxic and mediate antibody-dependent cellular cytotoxicity (ADCC) responses. NK cells can effectively treat tumors such as leukemia, but the therapeutic effect of NK cell adoptive immunotherapy in OC is still being explored. The promise of NK cell adoptive immunotherapy for OC was recognized in 2007, and it was shown that resting NK cells rely on DNAM-1 signaling with complementary contributions of NKG2D and NCR receptors to recognize and kill freshly isolated OC cells in vitro. In 2006, a new mouse model was established that will be helpful for further exploration of NK cell adoptive immunotherapy for OC.

**CIK Cells**

CIK cells were first discovered in 1991 by Schmidt-Wolf et al. They were heterogeneous CD8<sup>+</sup> T cells produced by human peripheral blood lymphocytes (PBLs) and induced by addition anti-CD3 antibody, interferon-γ (IFN-γ), and interleukin-2 (IL-2) ex vivo. CIK cells can be characterized by the presence of CD3<sup>+</sup>CD56<sup>+</sup> phenotype, which is mainly responsible for the antitumor activity of CIK cells and CD3<sup>+</sup>CD56<sup>−</sup> phenotype, which is more similar to conventional T lymphocytes.

Several studies have confirmed the feasibility, effectiveness, and safety of CIKs for the treatment of malignant tumors. Leemhuis et al confirmed the effectiveness of CIK cells in the treatment of malignant tumors, and then conducted a clinical phase I trial of CIK cell therapy in patients with hematologic malignancies. Clinical phase I trials of patients with hematologic malignancies by Introna et al also demonstrated that it was feasible and well tolerated to produce allogeneic CIK cells under clinical conditions. Another study analyzed the efficacy of CIK cells in the treatment of OC. In a phase II study, Liu et al tested the effectiveness of CIK cell therapy following first-line treatment in advanced OC. Further experiments are required to determine whether CIK cell maintenance immunotherapy can help improve overall survival, but CIK cell therapy does improve progression-free survival in patients with advanced OC after first-line treatment with slight toxicity. A retrospective analysis by Zhou et al further validated the effectiveness of CIK cell therapy as a therapeutic approach to prolonging the survival of OC patients.

A clinical phase II trial to determine whether radiofrequency ablation (RFA) and cytokine-induced killer
53 patients with OC currently believe that CAR-T cells are obtained recently discovered an effective treatment for OC, problems remain that limit its development. Although TIL cell adoptive immunotherapy for OC, costimulatory molecules such as CD28 and OX-40/4-1BB (CD134/CD137) were added in the second and third generation. The fourth generation is characterized by releasing cytokines like IL-12 and IL-15, which enhance immune response.

The most exciting results with CAR-T cell therapy have been achieved in hematological tumors. In a phase I clinical trial conducted by Park et al, 53 patients with relapsed B-cell acute lymphoblastic leukemia (ALL) received an infusion of autologous T cells expressing the 19-28z CAR. Long-term follow-up of outcomes and safety indicated that 19-28z CAR-T cells have potent anti-tumor capability with many patients achieving long-term relief and possibly cure. 63 Currently, anti-CD19 CAR-T cells are approved by the FDA for the treatment of diffuse large B-cell lymphoma. Brudno et al’s study of CAR-BCMA (B-cell maturation antigen) T cells in the treatment of multiple myeloma also confirmed the enormous potential of CAR-T cells in hematological tumor treatment. 64 Research on CAR-T cell therapy continues to extend to solid tumors including OC.

The main targets for CAR-T cells in OC include MUC16, mesothelin and folate receptor-α. Preclinical studies of CAR-T cell therapy targeting MUC16 in murine models have shown...
promising results suggesting that this approach may be effective for the treatment of OC, and a parallel clinical trial is ongoing. MUC16 plays an important role in the progression and metastasis of OC and has become a key target for OC treatment. Mesothelin is an antigen target that is overexpressed in OC. The expression of mesothelin is associated with the prognosis of OC; hence, mesothelin is both a therapeutic target for OC and a prognostic marker. The results of preliminary trials are promising, and more clinical trials on CAR-T cell therapy targeting mesothelin are still ongoing, such as NCT03692637 and NCT03814447. Folate receptor-α (FRα) is a glycosylphosphatidylinositol-anchored protein that expressed on the surface of normal ovarian cells. FRα is also overexpressed on the surface of malignant epithelial cancer cells, making it a potential target for the treatment of OC. The safety and efficacy of CAR-T cell therapy targeting FRα are supported by preclinical studies and phase I clinical trials. Another clinical trial (NCT03585764) is also underway. Other antigens such as HER2 and CD133 have also been tested in preclinical animal models for OC therapy (NCT01935843, NCT02541370).

Although CAR-T cell therapy has shown great potential in the treatment of OC, it still faces many problems that remain to be solved. The CAR target antigen is also expressed in some normal tissue, resulting in immune-mediated rejection that is known as an “on-target, off-tumor” response. This rejection can even cause damage to vital organs such as the liver and lungs. Also, the potentially immunosuppressive environment in OC, including the highly immunosuppressive ascites, will prevent T cells from effectively infiltrating into tumor cells and dysfunctional T cells. CAR-T cell adoptive immunotherapy also has some common problems of ACT treatment, such as cytokine release syndrome and a more effective T cell transport pathway. In conclusion, there are both hopes and challenges in the treatment of OC by CAR. Further research is necessary to improve the safety and efficacy of CAR-T cell therapy in OC.

TCR-T Cell Therapy

TCRs are characteristic markers on the surface of T cells that recognize specific antigens. TCR-T cells are T cells that express a genetically engineered TCR alpha and beta chain pair that can recognize tumor-specific antigens. TCR-T cell treatment has been successful in patients with malignant cancer such as colorectal carcinoma, metastatic melanoma, and multiple myeloma. Genetically modified TCR-T cells are also considered as a potentially promising treatment for OC patients. In OC, the TCR target antigens include MAGE-A4, WT1, and NY-ESO-1, with NY-ESO-1 being widely studied.

New York esophageal squamous cell carcinoma-1 (NY-ESO-1) is an 18 kDa protein that can be detected in normal testis, fetal ovary, and placenta. However, NY-ESO-1
antibodies can also be detected in the serum of ovarian cancer, lung cancer, breast cancer, bladder cancer, esophageal cancer, as well as melanoma patients. Odunsi et al detected the expression of NY-ESO-1 by reverse transcription PCR (RT-PCR) and immunohistochemistry (IHC) in OC tissues and cell lines, confirming its expression and persistence in OC. Thus, NY-ESO-1 is an attractive target for antigen-specific adoptive immunotherapy in OC. Several phase I/II clinical trials with TCR-T cells are currently ongoing in OC patients (NCT01567891, NCT03691376, NCT02457650, NCT02869217, NCT03159585). Like other types of ACT, there are barriers to the application of TCR-T cells to ACT. Tumor antigen-specific T cells of autoantigens isolated from cancer patients usually have low affinity due to central tolerance. As observed with CAR-T cells, the “on-target, off-tumor” response occurs when TCR-T cells are infused, due to the expression of the same antigen on normal tissue, and the infused TCR-T cells also induce the occurrence of cytokine release syndrome (CRS).

Although both TCR-T cells and CAR-T cells are genetically modified, they have several differences. Since TCRs can recognize epitopes from both intracellular and cell surface antigens of tumor cells via TAA/MHC complex, tumor-specific TCRs can only be used in patients with the specific MHC or HLA allele. In contrast, CAR recognition does not rely on peptide processing or MHC molecules; hence, CARs can only recognize tumor surface antigens; however, all surface target molecules may become potential CAR trigger epitopes.

### Obstacles For ACT In OC Immunosuppressive Tumor Microenvironment

Immune suppression in tumor microenvironment (TME) is mediated by three main factors: 1) immunosuppressive cells in the TME; 2) cytokines and enzymes released from the tumor or myeloid cells; and 3) barriers. An immunosuppressive TME seriously affects the therapeutic effect of ACT on tumors, especially in OC, which can build a highly suppressive environment in the peritoneal cavity.

T-regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs) are both important immunosuppressive cells in the OC TME. Tregs can induce immunosuppressive cytokines such as IL-10 and TGF-β to suppress the function of tumor-infiltrating cytotoxic T cells in the OC environment. MDSCs express high levels of substances such as arginase, inducible nitric oxide synthase (iNOS), and reactive oxygen species (ROS) to inhibit T-cell function. In order to reduce immunosuppression in TME, non-myeloablative chemotherapy can be used to decrease the number of Tregs and suppressive cellular cytokines. This can also be achieved by combinations of ACT with immune checkpoint inhibitors and targeted therapies. Some cytokines and enzymes released from the tumor or myeloid cells also can suppress the immune response. High expression of vascular endothelial growth factor (VEGF), which is expressed in most OC, can recruit MDSCs to the tumor site and inhibited tumor immunity in ovarian carcinoma. In tumor cells, the high expression of TGF-β will inhibit the function of human memory CD8 T cells and tumor-infiltrating lymphocytes. Indoleamine 2,3-dioxygenase (IDO) is an enzyme that catalyzes the degradation of tryptophan, which in turn inhibits T cell proliferation. In addition, IDO can directly inhibit T cells and enhance local Treg-mediated immunosuppression. To solve the immunosuppression caused by these cytokines and enzymes, we can combine antagonists and blocking antibodies for different targets with ACT treatment.

Tumor vasculature and tumor stroma are both common barriers that prevent homing of effector T cells. Leung et al suggested that cancer-associated fibroblasts (CAFs) can upregulate the lipoma-preferred partner (LPP) and this was correlated with survival and chemoresistance in patients with OC. They demonstrate the importance of CAF–endothelial cell crosstalk signaling in cancer treatment and the strategy of using LPP targeting siRNA in combination with cytotoxic drugs to improve treatment efficacy. Antiangiogenic agents are also being used to normalize the tumor vasculature and reduce the tumor metastasis in OC. A recent study showed that losartan has the effect of reducing collagen content as well as improving perfusion and relieving tumor hypoxia, and this is helpful to enhance chemotherapeutic efficacy in OC models.

### Cytokine Release Syndrome (CRS)

CRS is a potentially life-threatening acute inflammation that occurs after ACT infusion in hematologic and solid tumor patients. The typical clinical manifestations of CRS include constitutional symptoms like fever, malaise, anorexia, and myalgias, and organic damage like cardiac dysfunction, respiratory distress syndrome, and renal/hepatic/neurologic toxicity. CRS is caused by a massive cytokine release by the infused T
| NCT Number   | Status     | Conditions                                      | Type of Adoptive Therapy | Primary Outcome | Secondary Outcome | Adverse Events | Results                                                                 | Reference |
|--------------|------------|-------------------------------------------------|--------------------------|-----------------|-------------------|----------------|----------------------------------------------------------------------|-----------|
| NCT03692637 | Not yet recruiting | Epithelial Ovarian Cancer                        | Anti-Mesothelin CAR NK Cells | Occurrence of treatment-related adverse events | /                       | /                       | /                                                                    | /         |
| NCT03539406 | Not yet recruiting | Recurrent Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma | UCB-NK cells              | Incidence of treatment emergent adverse events | 1. In vivo lifespan and expansion of the infused UCB-NK cells 
2. Measurement of in vitro cytolytic activity of infused NK cells 
3. The effect of NK cell infusion on measurable disease | /                       | /                       | /                                                                    | /         |
| NCT00652899 | Terminated  | Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer | Allogeneic natural killer cells | Number of patients with in vivo expansion of infused allogeneic natural killer (NK) cell product | 1. Number of patients per disease response 
2. Median number of days to progression 
3. Median overall survival number of days patients alive after treatment | Hemolysis, Edema, Death - disease progression NOS, Fatigue, Fever, Dyspnea and so on | 1. None of the patients met the counting criteria in primary outcome. 
2. None of the patients had complete response, but most of patients had partial response or stable disease. 
3. Median number of days to progression was around 100 days. 
4. The median number of days survived after treatment was 291 for patients who did not receive total body irradiation per protocol, whereas it was 171.5 for patients who receive total body irradiation | /         |

(Continued)
| NCT Number | Status                  | Conditions                                                                 | Type of Adoptive Therapy                                                                 | Primary Outcome                                      | Secondary Outcome                                                                 | Adverse Events                                                                 | Results                                                                 | Reference |
|------------|-------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------------------|------------------------------------------------------|-----------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------|-----------|
| NCT02487693 | Active, not recruiting  | Ovarian Carcinoma                                                         | Autologous cytokine-induced killer cells                                               | Recurrence-free survival                            | Adverse events related to CIK treatments.                                        | /                                                                              | /                                                        | /          |
| NCT02482090 | Completed               | Metastatic Ovarian Cancer                                                 | TIL infusion                                                                          | Number and type of reported adverse events          | 1. Treatment-related immune responses                                             | /                                                                              | Young TILs could be expanded to clinical numbers. Autologous tumor cells are found in TILs in more than 50% of patients. Antigen-specific TILs could be isolated and further expanded in vitro. These findings suggested that ACT with TILs could be beneficial to patients with OC. | 53        |
| NCT03287674 | Active, not recruiting  | Metastatic Ovarian Cancer                                                 | TIL infusion                                                                          | Determine the safety of TIL therapy in combination with checkpoint inhibitors | 1. Treatment-related immune responses                                             | /                                                                              | /                                                        | /          |
| NCT03412526 | Recruiting              | Metastatic Ovarian Cancer                                                 | TIL infusion                                                                          | 1. Objective tumor responses 2. Assess adverse events | 1. OS and PFS 2. Response Rate (RR) 3. Quality of Life (QOL)                       | /                                                                              | /                                                        | /          |
| NCT03610490 | Recruiting              | Ovarian Carcinosarcoma, Recurrent Osteosarcoma, Recurrent Ovarian Carcinoma, Refractory Ovarian Carcinoma, etc | Autologous Tumor Infiltrating Lymphocytes MDA-TIL                                         | ORR                                                  | 1. Complete response rate (CRR) 2. Disease control rate (DCR) 3. Duration of response (DOR) 4. OS and PFS 5. Incidence of adverse events | /                                                                              | /                                                        | /          |

(Continued)
| NCT Number   | Status          | Conditions                                                        | Type of Adoptive Therapy | Primary Outcome                                      | Secondary Outcome                                                                                     | Adverse Events | Results                                                                 | Reference |
|--------------|-----------------|-------------------------------------------------------------------|--------------------------|-------------------------------------------------------|-------------------------------------------------------------------------------------------------------|----------------|----------------------------------------------------------------------------|-----------|
| NCT01883297  | Recruiting      | Recurrent, Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, etc | Re-stimulated           | Number occurrences and severity of side effects      | 1. Clinical response to treatment  
2. Number of patients with an immunity and no immunity to the study treatment | /              | /                                                                          | /         |
| NCT04025216  | Not yet recruiting | Non-Small Cell Lung Cancer, Ovarian Cancer, Fallopian Tube Cancer, Triple Negative Breast Cancer, Multiple Myeloma, Pancreatic Ductal Adenocarcinoma | TnMUC1-Targeted Genetically Modified Chimeric Antigen (CAR) | 1. Phase 1: Dose Identification of CART-TnMUC1  
2. Phase 1a Expansion: Objective Response in platinum-resistant ovarian cancer | 1. Safety, tolerability and feasibility of CART-TnMUC1  
2. Preliminary anti-tumor efficacy of CART as assessed by OS, PFS, ORR, Clinical Benefit Rate, DOR and Time to Response  
3. Expression of TnMUC1  
4. Peripheral expansion and persistence of CART-TnMUC1 cells | /              | /                                                                          | /         |
| NCT01583686  | Terminated      | Cervical Cancer, Pancreatic Cancer, Ovarian Cancer, Mesothelioma, Lung Cancer | Anti-mesothelin CAR transduced PBL | 1. Frequency and severity of treatment-related adverse events  
2. Percentage of patients who have a clinical response to treatment | In vivo survival of CAR gene-engineered cells | /              | Currently, the study only obtained experimental results related to monoclonal antibodies and published articles. | 113, 114   |
| NCT03916679  | Recruiting      | Ovarian Cancer                                                     | Anti-MESO CAR-T cells    | Safety measured by occurrence of study-related adverse effects | 1. Overall complete remission rate  
2. PFS after administration  
3. Duration of CAR-positive T cells in circulation  
4. Detection of PD-1 antibody in serum | /              | /                                                                          | /         |

(Continued)
| NCT Number | Status       | Conditions                                      | Type of Adoptive Therapy | Primary Outcome                                                               | Secondary Outcome                                                                 | Adverse Events | Results | Reference |
|------------|--------------|-------------------------------------------------|--------------------------|-------------------------------------------------------------------------------|----------------------------------------------------------------------------------|----------------|---------|-----------|
| NCT03585764 | Recruiting   | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | MOv19-BBz CAR T cells    | Number of study subjects with treatment-related adverse events               | 1. Tumor response rates 2. OS, PFS and ORR                                        | /              | /       | /         |
| NCT02830724 | Recruiting   | Pancreatic Cancer, Renal Cell Cancer, Breast Cancer, Melanoma, Ovarian Cancer | Anti-hCD70 CAR transduced PBL | 1. Maximum tolerated cell dose (MTD) 2. Percentage of patients who have a clinical response to treatment (objective tumor regression) | 1. In vivo survival of anti-hCD70 CAR transduced cells 2. Frequency and severity of treatment-related adverse events | /              | /       | /         |
| NCT03814447 | Recruiting   | Ovarian Cancer                                  | Anti- MESO CAR-T cells    | Adverse events (AEs) and Serious adverse event (SAEs)                        | 1. The highest concentration (Cmax), the time to reach the highest concentration (Tmax) and the area under the curve of 30 days of anti-human MESO T cells in the peripheral blood after administration 2. ORR and PFS after administration | /              | /       | /         |
| NCT02541370 | Unknown      | Ovarian Tumor, Colorectal Cancer, Acute Myeloid and Lymphoid Leukemias, etc | Anti-CD133 CAR T cells    | Occurrence of study-related adverse events                                   | Anti-tumor responses to CART-133 cell infusions                                   | Mild chills, Fever, Fatigue, Vomiting and Muscle soreness, etc | Currently, the study only obtained experimental results related to cholangiocarcinoma with published articles. | 115         |
| NCT Number       | Status       | Conditions                          | Type of Adoptive Therapy | Primary Outcome                                                                                   | Secondary Outcome                                                                 | Adverse Events                                                                 | Results                                                                                           | Reference |
|------------------|--------------|-------------------------------------|--------------------------|--------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|-----------|
| NCT01567891      | Completed    | Ovarian Cancer                      | NY-ESO-1\textsuperscript{259} T cells | Number of participants with adverse events related to study treatment                             | 1. Tumor response                                                                  | Febrile neutropenia, Cytokine Release Syndrome, Anemia, Sinus Tachycardia, Nausea, White blood cell and neutrophil count decreased, etc |
|                  |              |                                     |                          |                                                                                                  | 2. Peak persistence of modified T-cells in the peripheral blood                     |                                                                                             | 1. 5 out of 6 patients developed adverse events related to study treatment                   |
|                  |              |                                     |                          |                                                                                                  | 3. Determine functional properties and phenotype of modified T-cells from peripheral blood |                                                                                             | 2. No patient has a tumor response within the specified time range                           |
|                  |              |                                     |                          |                                                                                                  | 4. Correlate NY-ESO-I expression in tumor tissue before treatment with archival tumor tissue to assess impact of therapy on expression of NY-ESO-I protein |                                                                                             | 3. Peak persistence of NY-ESO-1\textsuperscript{259} T cells in the peripheral blood is 85.862.6 copies of WPRE/mcg of genomic PBMC DNA |
|                  |              |                                     |                          |                                                                                                  | 5. Data was only collected from 2 subjects. The Archival/ Baseline H scores of 2 subjects were 50/15 and 100/0 respectively. |                                                                                             | 4. In the manufactured product and post-treatment blood, the percentage of CD4\textsuperscript{+}pentamer\textsuperscript{-} or CD8\textsuperscript{+}pentamer\textsuperscript{-} cells expressing LAG-3, PD-1, TIM-3 in the functionality of NY-ESO-1\textsuperscript{259} T cells |
| NCT03159585      | Recruiting   | Stage IV of Ovarian Cancer, Esophageal Cancer, Bladder Carcinoma, etc | NY-ESO-1-specific TCR Affinity Enhancing Specific T Cell Therapy (TAEST16001) | The treatment-related adverse events of the patients received TAEST16001 treatment | Assess ORR, DOR, time to progress, PFS, OS and the expression of tumor markers             |                                                                                             | /                                                                                                 | /         |

(Continued)
### Table 2 (Continued).

| NCT Number | Status       | Conditions                                                                 | Type of Adoptive Therapy                              | Primary Outcome                                                                 | Secondary Outcome                                                                                                                                  | Adverse Events | Results | Reference |
|------------|--------------|-----------------------------------------------------------------------------|-------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|----------------|---------|-----------|
| NCT03691376 | Recruiting   | Platinum-Resistant/ Recurrent/Refractory Ovarian Carcinoma, Recurrent/Refractory Fallopian Tube Carcinoma, Recurrent/Refractory Primary Peritoneal Carcinoma | Autologous NY-ESO-1-specific CD8-positive T Lymphocytes | 1. Incidence of adverse events  
2. Maximum tolerated dose (MTD)                                                | 1. Immunological parameters associated with T cell persistence, bioactivity and functionality  
2. Tumor response rates to treatment  
3. PFS, OS and DOR  
4. Appearance of target antigen/major histocompatibility complex (MHC) loss variants upon disease recurrence | /                           | /                   | /         |
| NCT02457650 | Recruiting   | Ovarian Cancer, Bladder Carcinoma, Breast Cancer, Esophageus Carcinoma, Lung Cancer, etc | Anti-NY ESO-1 TCR-transduced T cells                  | Evaluate the safety and feasibility of the administration of anti-NY-ESO-1 TCR transduced T cells in patients with HLA-A2+ NY-ESO-1-expressing malignancies. | Determine if the treatment can result in clinical regression of malignant tumors in the patients.                                                  | /                           | /                   | /         |
| NCT02869217 | Recruiting   | Ovarian Cancer, Lung Cancer, Bladder Cancer, Liver Cancer                     | NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes (TBI-1301) | 1. Safety profile  
2. Recommended phase 2 (RP2D) dose TBI-1301 when administered following cyclophosphamide pre-treatment | Evidence of efficacy (i.e. anti-tumor effect) of TBI-1301                                                                  | /                           | /                   | /         |
cells or other immune cells that are activated as they recognize tumor antigens. IL-6 is a crucial mediator in CRS and is therefore an important target for the treatment of CRS.\textsuperscript{109} An antagonist of IL-6 receptor, tocilizumab, can alleviate the toxicity of CRS without affecting the therapeutic effect of ACT.\textsuperscript{109,110}

**On-Target, Off-Tumor Toxicity**

“Tumor-specific” antigens are also commonly expressed in normal tissues, which results in an on-target, off-tumor immune response after stimulation of T cells in ACT. If these antigens are expressed in vital organs, such as heart, liver, and kidney, they will cause fatal damage.\textsuperscript{74,75} The fundamental solution to this problem is to select tumor-specific antigens that are not expressed in normal tissues, but this is difficult. To overcome this, Kloss et al proposed a method where T cells are transduced with both a CAR, offering suboptimal activation upon binding of one antigen, and a chimeric costimulatory receptor (CCR) that recognizes a second antigen.\textsuperscript{111} This technology has made progress in OC. Lanitis et al generated trans-signaling T cells with two distinct CARs: anti-Meso scFv-CD3ζ and anti-FRα scFv-CD28.\textsuperscript{112} Both FRα and mesothelin show high expression in OC tissue, compared to much lower expression in normal tissues. The trans-signaling CAR strategy can more accurately identify tumor cells and diminish damage to normal tissues.

**Future Perspective**

Many clinical trials of ACT for ovarian cancer are ongoing [Table 2]. However, owing to the complexity of the OC tumor microenvironment and the human immune system, there are still many problems to be solved in the ACT treatment of OC. For example, how to reduce costs while ensuring efficient production of effector cells; and how infused T cells could home in on the tumor site and infiltrate it more accurately. Furthermore, many of the current clinical and preclinical experiments lack randomness, and more randomized trials are needed to confirm that ACT can improve overall survival (OS) or progression-free survival (PFS) in patients with ovarian cancer.

Nonetheless, in preclinical and clinical trials, the efficacy of ACT in OC is promising. Therefore, ACT still shows potential to become the new effective therapy for OC if we can address the abovementioned obstacles to reduce toxicity and improve the efficiency of ACT. The immune response inhibition caused by the tumor microenvironment can be reduced by combining the application of immunological checkpoint inhibitors or anti-angiogenesis agents, enabling improved effector cell function. In addition, new technology is evolving that utilizes two different CARs on T cells, enabling effector cells to more accurately identify tumor cells and improving their antitumor efficacy. Cell metabolism plays an important role in the anti-tumor effect of immune cells. Increasingly, studies have shown that the regulation of immune cell metabolism can affect the immune response;\textsuperscript{116–118} therefore, regulation of the effector cell metabolism process may be another approach to improve the anti-tumor effect and efficacy of ACT. Further refinement of technologies will hopefully generate more successful treatment methods for ovarian cancer.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136(5):E359–E386. doi:10.1002/ijc.29210
2. Elies A, Riviere S, Pouget N, et al. The role of neoadjuvant chemotherapy in ovarian cancer. *Expert Rev Anticancer Ther*. 2018;18(6):555–566. doi:10.1080/14772560.2018.1458614
3. Gorodnova TV, Sokolenko AP, Kuligina E, Berlev IV, Imyanitov EN. Principles of clinical management of ovarian cancer. *Chin Clin Oncol*. 2018;7(6):56. doi:10.21037/cco
4. Cho JH, Kim S, Song YS. Neoadjuvant chemotherapy in advanced ovarian cancer: optimal patient selection and response evaluation. *Chin Clin Oncol*. 2018;7(6):58. doi:10.21037/cco
5. Vargas-Hernandez VM, Moreno-Eutimio MA, Acosta-Altimirano G, Vargas-Aguilar VM. Management of recurrent epithelial ovarian cancer. *Gland Surg*. 2014;3(3):198–202. doi:10.3978/j.issn.2227-684X.2013.10.01
6. Monk BJ, Minion LE, Coleman RL. Anti-angiogenic agents in ovarian cancer: past, present, and future. *Ann Oncol*. 2016;27(Suppl 1):i33–i39. doi:10.1093/annonc/mdw093
7. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OFAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovarye (GINECO). *Cancer*. 2009;115(6):1234–1244. doi:10.1002/cncr.24149
8. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. *CA Cancer J Clin*. 2019;69(4):280–304. doi:10.3322/caac.21559
9. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med*. 2011;365(26):2473–2483. doi:10.1056/NEJMoa1104390
10. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. *N Engl J Med*. 2011;365(26):2484–2496. doi:10.1056/NEJMoa1103799
21. Wefers C, Lambert LJ, Torensma R, Hato SV. Cellular immunotherapy in ovarian cancer.

20. Coukos G, Tanyi J, Kandalaft LE. Opportunities in immunotherapy for ovarian cancer.

19. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. J Clin Oncol. 2015;33(34):4015–4022. doi:10.1200/JCO.2015.62.3397

23. Yang J, Loo C, Shreffler DC, et al. CD8α+ regulatory T cells in ovarian cancer. Ann Oncol. 2018;29(4):494–502. doi:10.1093/annonc/mdx344

24. Pakish JB, Jazaeri AA. Immunotherapy in gynecologic cancers: are we there yet? Curr Treat Options Oncol. 2018;19(12):74. doi:10.1007/s11864-018-0584-3

25. Zhang M, Zhang DB, Shi H. Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy. Immunotherapy. 2017;9(10):851–861. doi:10.2217/imt-2017-0039

26. Borítin MM, Rimn AA, Saltzstein EC. Graft versus leukemia: quantification of adoptive immunotherapy in murine leukemia. Science. 1973;179(4075):811–813. doi:10.1126/science.179.4075.811

27. Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563–571. doi:10.1038/s41591-018-0010-i

28. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850–854. doi:10.1126/science.1076514

29. Dudley ME, Yang J, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233–5239. doi:10.1200/JCO.2008.16.5449

30. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346–2357. doi:10.1200/JCO.2005.00.240

31. Liu YL, Zamarin D. Combination immune checkpoint blockade strategies to maximize immune response in gynecological cancers. Curr Oncol Rep. 2018;20(12):94. doi:10.1007/s11912-018-0740-8

32. Perica K, Varela JC, Oelke M, Schneck J. Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med J. 2015;6(1):e0004. doi:10.5041/RMMJ.20150012

33. Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med. 1986;164(3):814–825. doi:10.1084/jem.164.3.814

34. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313(23):1485–1492. doi:10.1056/NEJM19853132327

35. Grimm EA. Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality. Biochim Biophys Acta. 1986;865(3):267–279. doi:10.1016/0304-419X(86)90017-x

36. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2009;10(5):503–510. doi:10.1038/ni1582

37. Lopez-Soto A, Gonzalez S, Smyth M, Galluzzi L. Control of metastasis by NK cells. Cancer Cell. 2017;32(2):135–154. doi:10.1016/j.ccell.2017.06.009

38. Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer. 1975;16(2):230–239. doi:10.1002/ijc.2910160205

39. Kiesling R, Klein E, Pross H, Wigzell H. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse myeloma leukemia cells. Characteristics of the killer cell. Eur J Immunol. 1975;5(2):117–121. doi:10.1007/bf01830520

40. Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016;17(9):1025–1036. doi:10.1038/ni.3518

41. Baragano Raneros A, Lopez-Larrea C, Suarez-Alvarez B. Acute myeloid leukemia and NK cells: two warriors confront each other. Oncocimmunology. 2019;8(2):e1539617. doi:10.1080/2162402X.2018.1539617

42. Carlsten M, Bjorkstrom NK, Norell H, et al. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 2007;67(3):1317–1325. doi:10.1158/0008-5472.CAN-06-2264

43. Hermanson DL, Bendzick L, Kaufman DS. Mouse xenograft model for intraperitoneal administration of NK cell immunotherapy for ovarian cancer. Methods Mol Biol. 2016;1441:277–284. doi:10.1007/7987-14939-3684-7_23

44. Schmidt-Wolf IG, Negrin RS, Kiern HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytotoxic-killed cell vaccines with potent antitumor cell activity. J Exp Med. 1991;174(1):139–149. doi:10.1083/jem.174.1.139

45. Linn YC, Lau LC, Hui KM. Generation of cytotoxic-killed cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol. 2002;116(1):78–86. doi:10.1046/j.1365-2457.2002.02347.x

46. Leenhuys T, Wells S, Schefold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-killed killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005;11(3):181–187. doi:10.1016/j.bbmt.2004.11.019

47. Introna M, Borleri G, Conti E, et al. Repeated infusions of donor-derived cytokine-killed killer cells in patients relapsing after allogenic stem cell transplantation: a phase I study. Haematologica. 2007;92(7):952–959. doi:10.3324/haematol.11132

48. Liu J, Li H, Cao S, et al. Maintenance therapy with autologous cytokine-killed killer cells in patients with advanced epithelial ovarian cancer after first-line treatment. J Immunother. 2014;37(2):115–122. doi:10.1097/CIT.0000000000000021
49. Zhou Y, Chen CL, Jiang SW, et al. Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy. *Oncoimmunology*. 2019;8(2):e1528411. doi:10.1080/2162402X.2018.1528411

50. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. *Cancer Res*. 2011;71(13):4550–4557. doi:10.1158/0008-5472.CCR-11-0116

51. Aoki Y, Takakuwa K, Kodama S, et al. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. *Cancer Res*. 1991;51(7):1934–1939.

52. Fujita K, Ikarashi H, Takakuwa K, et al. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. *Clin Cancer Res*. 1995;1(5):501–507.

53. Westergaard MCW, Andersen R, Chong C, et al. Tumour-reactive T cell subsets in the microenvironment of ovarian cancer. *Br J Cancer*. 2019;120(4):424–434. doi:10.1038/s41416-019-0384-y

54. Radestad E, Klynning C, Stikvoort A, et al. Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer. *Oncoimmunology*. 2019;8(2):e1535730. doi:10.1080/2162402X.2018.1535730

55. Owens GL, Price MJ, Cheadle EJ, Hawkins RE, Gilham DE, Edmondson RJ. Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells. *Cancer Immunol Immunother*. 2018;67(10):1519–1531. doi:10.1007/s00262-018-2281-3

56. Dudley ME, Wunderlich JR, Sheltone TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. *J Immunother*. 2000;23(4):332–342.

57. Junker N, Andersen MH, Wenandy L, et al. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer. *Cytotherapy*. 2011;13(7):822–834. doi:10.3109/14653249.2011.563291

58. Priceman SJ, Forman SJ, Brown CE. Smart CARs engineered for cancer immunotherapy. *Curr Opin Oncol*. 2015;27(6):466–474. doi:10.1097/CCO.0000000000000232

59. Lim M, Xia Y, Bettegović C, Weller M. Current state of immunotherapy for glioblastoma. *Nat Clin Pract Oncol*. 2018;15(7):422–442. doi:10.1038/s41571-018-0033-5

60. Met O, Jensen KM, Chamberlain CA, Doria M, Svane IM. Principles of adoptive T cell therapy in cancer. *Semin Immunopathol*. 2019;41(1):49–58. doi:10.1007/s00281-018-0703-z

61. Wang L, Xu T, Cui M. Are ovarian cancer stem cells the target for MUC16 antigen. *Oncol Lett*. 2018;36(22):2267–2280. doi:10.3892/ol.2018.7738084

62. Chekmasova AA, Rao TD, Nikhamin Y, et al. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. *Clin Cancer Res*. 2010;16(14):3594–3606. doi:10.1158/1078-0432.CCR-10-0192

63. Felder M, Kapur A, Gonzalez-Bosquet J, et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. *Mol Cancer*. 2014;13:129. doi:10.1186/1476-4598-13-129

64. Hassan R, Kreitman RJ, Pasant I, Willingham MC. Localization of mesothelin in epithelial ovarian cancer. *Appl Immunohistochem Mol Morphol*. 2005;13(3):243–247.

65. Yen MJ, Hsu CY, Mao TL, et al. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. *Clin Cancer Res*. 2006;12(3 Pt 1):827–831. doi:10.1158/1078-0432.CCR-05-1397

66. Kalli KR, Oberg AL, Keeney GL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. *Gynecol Oncol*. 2008;108(1):619–626. doi:10.1016/j.ygyno.2007.11.020

67. Mohamed K, Cermignuolo C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancers. *Int J Cancer*. 1997;74(2):193–198. doi:10.1002/(sici)1097-0215(19970202)74:2<193::aid-ijc10>3.0.co;2-f

68. Kallina BF, Powell DJ Jr., Koukos G. A phase I clinical trial of adoptive transfer of folate-receptor-alpha redirected autologous T cells for recurrent ovarian cancer. *J Transl Med*. 2012;10:157. doi:10.1186/1479-5876-10-233

69. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurentuc CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. *Mol Ther*. 2010;18(4):835–841. doi:10.1038/mt.2010.24

70. Cai B, Guo M, Wang Y, et al. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukaemia. *J Hematol Oncol*. 2016;9(1):131. doi:10.1186/s13045-016-0357-z

71. Germain RN, Stefanova I. The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. *Annu Rev Immunol*. 1999;17:467–522. doi:10.1146/annurev.immunol.17.1.467

72. van der Merwe PA, Davis MJ. Molecular interactions mediating T cell antigen recognition. *Annu Rev Immunol*. 2003;21:659–684. doi:10.1146/annurev.immunol.21.120601.141036

73. Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. *Mol Ther*. 2011;19(3):620–626. doi:10.1038/mt.2010.272

74. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. *Science*. 2008;314(5796):126–129. doi:10.1126/science.1129003

75. Robbins PF, Kassim SH, Tran TL, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. *Clin Cancer Res*. 2015;21(5):1019–1027. doi:10.1158/1078-0432.CCR-14-2708

76. San Miguel JF, Paiva B, Lasarte JI. Engineering Anti-myeloma responses using affinity-enhanced TCR-engineered T cells. *Cancer Cell*. 2015;28(3):281–283. doi:10.1016/j.ccell.2015.08.009

77. Matsuda T, Leisegang M, Park JH, et al. Induction of neoantigen-specific cytotoxic T cells and construction of T-cell receptor-engineered T cells for ovarian cancer. *Clin Cancer Res*. 2018;24(21):5357–5367. doi:10.1158/1078-0432.CCR-18-0142

78. Jungbluth AA, Chen YT, Stockert E, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. *Int J Cancer*. 2001;92(6):856–860. doi:10.1002/ijc.1282

79. Odunsi K, Jungbluth AA, Stockert E, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. *Cancer Res*. 2003;63(18):6076–6083.
85. Schmitt TM, Aggen DH, Ishida-Tsukuba K, Ochsenreither S, Kranz DM, Greenberg PD. Generation of higher affinity T cell receptors by antigen-driven differentiation of progenitor T cells in vitro. Nat Biotechnol. 2017;35(12):1188–1195. doi:10.1038/nbt.4004

86. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74–80. doi:10.1126/science.aab6204

87. Stone ML, Chiappinelli KB, Li H, et al. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc Natl Acad Sci U S A. 2017;114(49):E10990–E10999. doi:10.1073/pnas.1712514114

88. Li L, Wang L, Li J, et al. Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer. Cancer Res. 2018;78(7):1779–1791. doi:10.1158/0008-5472.CAN-17-2460

89. Curiel TJ, Coulkos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942–949. doi:10.1038/nm1093

90. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61(12):4766–4772.

91. Chen ML, Wittke MJ, Gorelik L, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A. 2005;102(2):419–424. doi:10.1073/pnas.0408197102

92. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–174. doi:10.1038/nri2506

93. Marcel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015;125(9):3356–3364. doi:10.1172/JCI80005

94. Gattinoni L, Finkelson SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005;202(7):907–912. doi:10.1084/jem.20050732

95. Mitsui J, Nishikawa H, Murooka D, et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res. 2010;16(10):2781–2791. doi:10.1158/1078-0432.CCR-09-3243

96. Cacini S, Staccioli MP, Gasparini G, et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res. 2000;6(7):2803–2807.

97. Brustmann H, Naude S. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage. Gynecol Oncol. 2002;84(1):47–52. doi:10.1006/gyno.2001.6647

98. Horikawa N, Abiko K, Matsumura N, et al. Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells. Clin Cancer Res. 2017;23(2):587–599. doi:10.1158/1078-0432.CCR-16-0387

99. Ahmadzadeh M, Rosenberg SA. TGF-beta1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8+ T cells. J Immunol. 2005;174(9):5215–5223. doi:10.4049/jimmunol.174.9.5215

100. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117(5):1147–1154. doi:10.1172/JCI31178

101. Natarajan S, Foreman KM, Soriano MI, et al. Collagen remodeling in the hypoxic tumor-mesothelial niche promotes ovarian cancer metastasis. Cancer Res. 2019;79(9):2271–2284. doi:10.1158/0008-5472.CAN-18-2616

102. Leung CS, Yeung TL, Yip KP, et al. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Invest. 2018;128(2):589–606. doi:10.1172/JCI95200

103. Zhao Y, Cao J, Melamed A, et al. Losartan treatment enhances antitumor activity of CD8(+) memory CD8(+) T cells in a patient with advanced cholangiocarcinoma. Clin Cancer Res. 2019;25(2):329–338. doi:10.1158/1078-0432.CCR-17-3279

104. Li L, Wang L, Li J, et al. Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer. Cancer Res. 2018;78(7):1779–1791. doi:10.1158/0008-5472.CAN-17-2460

105. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942–949. doi:10.1038/nm1093

106. Wool EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61(12):4766–4772.

107. Chen ML, Wittke MJ, Gorelik L, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A. 2005;102(2):419–424. doi:10.1073/pnas.0408197102

108. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–174. doi:10.1038/nri2506

109. Marcel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015;125(9):3356–3364. doi:10.1172/JCI80005

110. Gattinoni L, Finkelson SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005;202(7):907–912. doi:10.1084/jem.20050732

111. Mitsui J, Nishikawa H, Murooka D, et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res. 2010;16(10):2781–2791. doi:10.1158/1078-0432.CCR-09-3243

112. Cacini S, Staccioli MP, Gasparini G, et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res. 2000;6(7):2803–2807.

113. Brustmann H, Naude S. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage. Gynecol Oncol. 2002;84(1):47–52. doi:10.1006/gyno.2001.6647

114. Horikawa N, Abiko K, Matsumura N, et al. Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells. Clin Cancer Res. 2017;23(2):587–599. doi:10.1158/1078-0432.CCR-16-0387

115. Ahmadzadeh M, Rosenberg SA. TGF-beta1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8+ T cells. J Immunol. 2005;174(9):5215–5223. doi:10.4049/jimmunol.174.9.5215

116. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117(5):1147–1154. doi:10.1172/JCI31178

117. Natarajan S, Foreman KM, Soriano MI, et al. Collagen remodeling in the hypoxic tumor-mesothelial niche promotes ovarian cancer metastasis. Cancer Res. 2019;79(9):2271–2284. doi:10.1158/0008-5472.CAN-18-2616
OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal